// App-Quantinova.ai

EXTH-46 : ARTIFICIAL INTELLIGENCE-BASED IDENTIFICATION OF COMBINED VANDETANIB AND EVEROLIMUS IN THE TREATMENT OF ACVR1-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA

Researchers

Presenter

  • Diana Carvalho

Principal Investigators

  • Nagore Gene Olaciregui

  • Reda Stankunaite

  • Cinzia Emilia Lavarino

  • Valeria Molinari

  • Elizabeth Corley

  • Ruth Ruddle

  • Adam Donovan

  • Akos Pal

  • Florence I Raynaud

  • John P Overington

  • Anne Phelan

  • Dave Sheppard

  • Andrew Mackinnon

  • Michael Hubank

  • Ofelia Cruz

  • Andres Morales La Madrid

  • Sabine Mueller

  • Angel Montero Carcaboso

  • Fernando Carceller

  • Chris Jones

Medical Centers

  • Institute for Cancer Research, London, United Kingdom

  • BenevolentAI London United Kingdom

  • Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain

  • The Royal Marsden Hospital, London, United Kingdom

  • Hospital Sant Joan de Déu, Barcelona, United Kingdom

  • University of California, San Francisco, San Francisco, CA

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse intrinsic pontine glioma

  • Cerebral metastases

  • Gliomas

Biomarkers

  • ATP Binding Cassette Transporter B1

  • ATP-binding cassette super-family G member 2

  • Ret Proto-Oncogene

  • Epidermal growth factor receptor

  • Kinase Insert Domain Receptor

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Everolimus

  • Vandetanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved